Migraine Med Shows Weight-Loss Benefit

Published Date: 30 Apr 2026

New data show early and sustained weight loss with atogepant, raising the possibility of metabolic benefits beyond migraine prevention.

Read Full News

Latest News

Novo Nordisk Flags Patient Data Breach From Some Clinical Trials in Cyberattack

Novo Nordisk said on Thursday it has identified a security incident in which certain information, including ⁠patient data from some clinical trials, was copied externally...

Tirzepatide Outperforms Conventional Care in Early Diabetes

Tirzepatide offered better glycemic control and greater weight loss than intensive conventional care in adults with early type 2 diabetes, a study finds.

AI-Guided Prep Improves Bariatric Surgery Consults

A structured, AI-supported metacognitive framework substantially enhances the quality of metabolic and bariatric surgery consultations.

PMOS: Insulin Resistance Affects Fertility and Pregnancy

Prepregnancy insulin resistance is associated with impaired fertility and increased pregnancy complications such as preeclampsia.

Over-the-Counter CGM Okayed for Kids

The US FDA extended the age of use for Dexcom’s Stelo down to 2 years.

Novel Oral GLP-1 Shows A1c and Weight-Loss Benefits

The new drug would add another oral GLP-1 with no fasting or fluid intake restrictions to clinicians’ toolboxes, improving options for targeted treatment.

Todays Updates

HIV Care Coordination Program May Reduce Deaths in NYC

New York City’s revised Care Coordination Program may help reduce risks for all-cause and HIV-related deaths among people with HIV infection, including those at the highest risk for poor outcomes.

Teplizumab Approved for Pediatric Stage 3 Type 1 Diabetes

The drug was previously approved for stage 2 T1D.

One in Four Teen Girls and Young Women at Risk for PMOS

Findings suggest young females should be assessed and, if at risk, monitored.

Palopegteriparatide Benefits Sustained Beyond 3 Years

Final results from the PaTHway trial show the long-acting parathyroid hormone therapy enabled patients with hypoparathyroidism to achieve independence from high-dose calcium and vitamin D supplements.

Testosterone Prescribing Often Ignores Guidelines

Only 12% of patients prescribed testosterone underwent appropriate diagnostic testing, and overprescribing was common in a single-center US study.

Encaleret Shows Rapid Response in ADH1

The oral modulator of the calcium-sensing receptor targets the causes of ADH1, significantly improving serum and urine calcium levels.

Off-Label Rxs: Thinking Out of the Box for Skin Diseases

Off-label alternatives for FDA-approved therapies can be as effective, cheaper, and in some cases safer despite never having been submitted for regulatory approval.

Todays Updates

HIV Care Coordination Program May Reduce Deaths in NYC

New York City’s revised Care Coordination Program may help reduce risks for all-cause and HIV-related deaths among people with HIV infection, including those at the highest risk for poor outcomes.

Teplizumab Approved for Pediatric Stage 3 Type 1 Diabetes

The drug was previously approved for stage 2 T1D.

One in Four Teen Girls and Young Women at Risk for PMOS

Findings suggest young females should be assessed and, if at risk, monitored.

Palopegteriparatide Benefits Sustained Beyond 3 Years

Final results from the PaTHway trial show the long-acting parathyroid hormone therapy enabled patients with hypoparathyroidism to achieve independence from high-dose calcium and vitamin D supplements.

Testosterone Prescribing Often Ignores Guidelines

Only 12% of patients prescribed testosterone underwent appropriate diagnostic testing, and overprescribing was common in a single-center US study.

Encaleret Shows Rapid Response in ADH1

The oral modulator of the calcium-sensing receptor targets the causes of ADH1, significantly improving serum and urine calcium levels.

Off-Label Rxs: Thinking Out of the Box for Skin Diseases

Off-label alternatives for FDA-approved therapies can be as effective, cheaper, and in some cases safer despite never having been submitted for regulatory approval.

Latest News

Novo Nordisk said on Thursday it has identified a security incident in which certain information, including ⁠patient data from some clinical trials, was copied externally...

Tirzepatide offered better glycemic control and greater weight loss than intensive conventional care in adults with early type 2 diabetes, a study finds.

A structured, AI-supported metacognitive framework substantially enhances the quality of metabolic and bariatric surgery consultations.

Prepregnancy insulin resistance is associated with impaired fertility and increased pregnancy complications such as preeclampsia.

The US FDA extended the age of use for Dexcom’s Stelo down to 2 years.

The new drug would add another oral GLP-1 with no fasting or fluid intake restrictions to clinicians’ toolboxes, improving options for targeted treatment.

News All Time

Wearables Generate the Data: What's Next for Chronic Care?

Wearable devices are moving beyond fitness tracking, providing clinicians with real-world data that may improve monitoring and continuity of care in chronic disease.

Beyond BMI: New Score Stratifies Obesity Risk

BMI, while useful, is insufficient to identify patients at the highest risk for obesity-related complications. A new tool may help clinicians better stratify risk and target treatment.

Tango Therapeutics' Pancreatic Cancer Drug Combo Shows Promise in Study

Tango Therapeutics said on Monday an experimental drug combination showed strong early results in a small study of patients ⁠with advanced pancreatic cancer and that it...

Liver-Directed Insulin: A New Way to Reduce Hypoglycemia?

Study findings suggest that a liver-targeted formulation of fast-acting insulin may reduce the risk for hypoglycemia in patients with type 1 diabetes.

Moving Beyond GLP-1s: Preclinical Acceleration, Innovation

Next-generation obesity therapeutics aim to counter weight rebound, decrease side effects, and support weight maintenance.

Dual Incretin Agonist Survodutide Benefits Liver in Phase 3

The glucagon receptor/GLP-1 receptor dual agonist reduces weight, visceral fat, and liver fat.

From Taboo to Test: Can Menstrual Blood Aid Diagnosis?

Emerging research suggests that menstrual blood may provide valuable diagnostic and biological insights, with potential applications in cancer screening and endometriosis detection.

Do Corticosteroids Really Raise Gestational Diabetes Risk?

Emerging research says the steroids aren’t a major driver of gestational diabetes, but impacts vary depending on the patient.

Petrelintide Tolerability Could Improve on GLP-1 Challenges

The amylin analog petrelintide reduces body weight with 'placebo-like' tolerability, a phase 2 trial shows.

No Increased Retinopathy Risk Seen With Tirzepatide

No changes in diabetic retinopathy status occurred in high-risk people with type 2 diabetes taking tirzepatide when compared with dulaglutide.

GLP-1 QOL Benefits Greatest for Those With Obesity Plus T2D

Patients with obesity and type 2 diabetes have more favorable QOL outcomes taking a GLP-1 than those with either condition alone or with multiple comorbidities.

Obesity Meds Improve Patients' Perceived Physical Function

Obesity management medications improve patients' perceived physical function and have a 'modest' impact on an objective functional measure.

CGM Monitoring Benefits Extend to Non-Insulin-Using T2D

Patients with type 2 diabetes not taking insulin who use continuous glucose monitoring show significant reductions in A1c.

Glucose Excursions Drive CGM-A1c Discordance in Monitoring

Discordance between continuous glucose monitoring measures and A1c should not always be interpreted as measurement errors, according to a new study.

Danish Study Links Type 1 Diabetes to Femoral Fractures

Both T1D and T2D are linked to a higher incidence of subtrochanteric or femoral shaft and hip fractures, but after adjusting for age, only the association for T1D remains significant.

Primary Infertility Linked to Earlier Menopause Onset

Women with primary infertility undergo natural menopause earlier than women without infertility.

Recommended News For You

World's premier cancer institute faces crippling cuts and chaos

Patient Endured 9 Years of Chemotherapy for Cancer He Never Had

New imaging guidelines for head and neck cancers, a step toward practice change

A retrospective study examined the role of CA 19-9 and CEA in duodenal adenocarcinoma prognosis.

AI Breath Test IDs Cancers; More Grief for Prior Auth; Imatinib Discoverer Resigns

Data indicate 1 in 3 US adults unaware of connection between HPV and cancers

NEET SS Counseling 2023: MCC provides information on DNB SS Medical Oncology seats available at ESIC Medical College and Hospital Faridabad.

Recommended Articles For You

Vaccines that can help prevent cancer 

Innovative Advances in Oncology for Specialists 

Revolutionizing Thyroid Cancer: Advances in Molecular Genetics and Personalized Treatment Approaches 

Unlocking the Secrets of Improved Ovarian Cancer Survival Rates 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Molecular profiling of renal medullary carcinoma identifies TROP2 as a promising therapeutic target

2.

Is global cancer care losing its human touch?

3.

New study links air pollution with higher rates of head and neck cancer

4.

Can Children With Low-Risk Hodgkin Lymphoma Skip Radiation?

5.

Avoiding Neuropathy From Chemo; Predictive Value of Screening EKGs

1.

Contemporary Trends in Oncology and Patient Outcomes

2.

Survival Rates in Cancer: Focus on Acute Myeloid Leukemia and Other Malignancies

3.

Multimodal Data Fusion with Deep Neural Networks - Revolutionizing Oncology with Precision Cancer Diagnosis 2025

4.

Emerging Frameworks in Oncology in Clinical Decision-Making

5.

The Basics of M.C.V Normal Range for Better Health Management

1.

Asian Symposium on Advancement in Hematology and Oncology

2.

Asian Symposium on Advancement in Hematology and Oncology

3.

International Cancer Conference

4.

Asian Symposium on Advancement in Hematology and Oncology

5.

International Lung Cancer Congress®

1.

Rates of CR/CRi and MRD Negativity in Iontuzumab-Treated Patients

2.

First-Line Maintenance Therapy for Metastatic Urothelial Carcinoma: Bridging Clinical Practice and Trials

3.

The Landscape of First-Line Treatment for Urothelial Carcinoma- The Conclusion

4.

The Landscape of First-Line Treatment for Urothelial Carcinoma- Further Discussion

5.

Newer Immunotherapies for Myeloma- A Comprehensive Overview- Part II

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot